Results 71 to 80 of about 212,475 (307)

Immunomodulatory Effect of Fennel in Animal Model of Polycystic Ovarian Syndrome

open access: yesMajallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk, 2020
Background and Aim: Fennel with phytoestrogenic, antioxidant and anti-diabetic properties is used in traditional Iranian medicine to treat Polycystic Ovarian Syndrome (PCOS).
Ensieh Seif Amirhoseiny   +3 more
doaj  

TCF1 and LEF1 Control Treg Competitive Survival and Tfr Development to Prevent Autoimmune Diseases. [PDF]

open access: yes, 2019
CD4+ Foxp3+ T regulatory (Treg) cells are key players in preventing lethal autoimmunity. Tregs undertake differentiation processes and acquire diverse functional properties.
Cho, Sunglim   +12 more
core   +1 more source

Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer [PDF]

open access: yes, 2016
Tregs can contribute to tumor progression by suppressing antitumor immunity. Exceptionally, in human colorectal cancer (CRC), Tregs are thought to exert beneficial roles in controlling pro-tumor chronic inflammation.
BARNABA, Vincenzo   +14 more
core   +1 more source

The Aging Blood: Cellular Origins, Circulating Drivers, and Therapeutic Potential

open access: yesAging and Cancer, EarlyView.
As a conduit linking all organs, the blood system both reflects and actively drives systemic aging. This review highlights how circulating pro‐aging and antiaging factors and age‐associated hematopoietic stem cell dysfunction contribute to immunosenescence and multi‐organ decline, positioning the hematopoietic system as a target for aging intervention.
Hanqing He, Jianwei Wang
wiley   +1 more source

Depletion of CD25+ cells during acute toxoplasmosis does not significantly increase mortality in Swiss OF1 mice

open access: yesMemorias do Instituto Oswaldo Cruz, 2012
The interleukin (IL)-2R alpha chain (CD25) is expressed on regulatory T cells (Treg), which constitute more than 85% of the CD25+ T cell population in a naïve mouse.
Haroon Akbar   +4 more
doaj   +1 more source

Role of CD4+CD25+FOXP3+ TReg cells on tumor immunity

open access: yesImmunological Medicine, 2021
Not all T cells are effector cells of the anti-tumor immune system. One of the subpopulations of CD4+ T cells that express CD25+ and the transcription factor FOXP3, known as Regulator T cells (TReg), plays an essential role in maintaining tolerance and ...
Agustinus Darmadi Hariyanto   +2 more
doaj   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo   +9 more
wiley   +1 more source

CLEC5a-directed bispecific antibody for effective cellular phagocytosis

open access: yesmAbs, 2022
While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB).
Vivekananda Kedage   +11 more
doaj   +1 more source

Expansion of CD25-Negative Forkhead Box P3-Positive T Cells during HIV and Mycobacterium tuberculosis Infection [PDF]

open access: yes, 2017
Tuberculosis (TB) and HIV alter the immune system, and coinfected (HIV-TB) individuals usually present deregulations of T-lymphocytic immune response.
Ameri, Diego   +9 more
core   +2 more sources

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy